Invitation to webcast ‘Benefit from Time’ - Panel Discussion from XVIIIth World Congress of Neurology

Welcome to follow a webcast of world leading experts discussing new data for Betaferon® and its potential implications for Multiple Sclerosis (MS) treatment. Just go to www.benefitfromtime.com and follow the instructions.

WHY: Betaferon® has been on the market for 16 years and has been proven to be an effective and well-tolerated therapy for relapsing forms of MS. Trial were presented that point to a possible advance in the way that patients at risk of MS are treated, through early intervention. We have assembled a panel of experts from around the world to discuss this data and its implications. WHEN: Friday 11th, November 2005 at 10:30 AM CET (Europe) The webcast will be archived for three months. WHERE: www.benefitfromtime.com A cd will be available after the congress for those who wants to order. Panelists: Professor George Ebers, lead author of the 16-LTF study Professor David Bates, Chairman, MS Forum Professor Mark Freedman, Director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, Canada Professor Luca Durelli, Chief, MS Centre of University Department of Neurosciences, Turin, Italy Lindsay McMillan, Victorian and NSW MS Society The Hon. Michael Wooldridge, former Federal Minister for Health, Australia Dr John King, President, Australian Association of Neurologists Dr John D’Arcy (Moderator) Welcome! For further information or contact with Scandinavian experts involved in the research, please contact Lisa Emilsson, Corporate Communication Manager, Schering Nordiska AB: +46 70 635 72 20; lisa.emilsson@schering.de For more background information regarding Multiple Sclerosis, the study BENEFIT or Betaferon, please see www.ms-portalen.com